Skip to content Skip to left sidebar Skip to footer

New Vaccine Product Available Through VFC: Penbraya (MenABCWY)

New Vaccine Product Available Through VFC: Penbraya (MenABCWY)

On October 20, 2023, the FDA licensed Pfizer’s pentavalent vaccine Penbraya to prevent meningococcal serogroups A, B, C, W, and Y.

As a reminder, MenB vaccines are not interchangeable. The same vaccine (either Bexsero by GSK or Trumenba by Pfizer) must be used for all doses in the MenB series, including booster doses. The pentavalent MenABCWY product Penbraya (Pfizer) contains MenB-Fhbp (Trumenba) as its MenB component; therefore, Penbraya should only be used in series with Trumenba.

To add this formulation to the list of vaccines that your site orders, use the button below to complete the change request form.

Our team will review your request and reply with next steps. We recommend that sites that are affiliated or part of a system use the same vaccine presentations across sites to ensure continuity of care and help prevent administration errors.

To purchase this vaccine in the private market, please contact your local Pfizer sales rep at

Penbraya 1 Dose Kit and Penbraya 5 Dose Kit are now available through the Vaccines for Children (VFC) program. 

  • The Advisory Committee on Immunization Practices (ACIP) recommends MenABCWY for ages 10 through 25. Penbraya may be used when both MenACWY and MenB are indicated at the same visit. More specifically, MenABCWY is recommended for the following groups based on shared clinical decision-making:
  • Healthy individuals aged 16 to 23 years due for their MenACWY booster and MenB vaccination at the same visit. 
  • Children 10 years and older with complement deficiency, functional or anatomic asplenia (including sickle cell disease), or receiving complement inhibitors. 
  • CVX code: 316 
  • CPT code: 90623 
  • NDC number: 00069-0600-01 (1 Dose Kit) and 00069-0600-05 (5 Dose Kit) 


If you have any questions, please email